Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
NCT02100514
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
746
Enrollment
INDUSTRY
Sponsor class
Conditions
Hyperlipidemia
Interventions
DRUG:
Bococizumab (PF-04950615; RN316)
OTHER:
Placebo
Sponsor
Pfizer